CliffBio
small molecule

RISVAN

RISPERIDONE

Loss of exclusivityMay 2031latest FDA-listed patent expiry
CompanyLaboratorios Farmaceuticos Rovi →View the full company profile on CliffBio

Drug detail

Brand nameRISVAN
Active ingredientRISPERIDONE
Strength100MG
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalMarch 2024
Marketing statusDISCN

Listed patents

PatentExpiresType
11752092May 2031use U-3941
11241377May 2031use U-3939
11173110May 2031use U-3941
11007139May 2031use U-3942
10195138May 2031use U-3943
10182982May 2031use U-3943
11759416May 2031use U-3939
11752094May 2031use U-3942
10881605May 2031product
10058504May 2031product
10085936May 2031product
10463607May 2031product
11752093May 2031product
10335366May 2031product

Regulatory exclusivity

CodeExpires
NPMarch 2027

More from Laboratorios Farmaceuticos Rovi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RISVAN patent cliff — loss of exclusivity May 2031 | CliffBio